Cixutumumab (Anti-IGF1R / CD221) | Read Reviews & Product Use Citations

Cixutumumab (Anti-IGF1R / CD221) is a humanized monoclonal antibody with high affinity that targets type-1-insulin-like growth factor receptor (IGF-1R).It shows broad-spectrum anti-tumour activity and can be used in studies of sarcomas, neuroblastoma, wilms tumor, lung cancer, malignancies, leukaemia, non-small cell lung cancer and prostate cancer. MW :150 KD.

Purity & Quality Control

≥99

Biological Activity

Description	Cixutumumab (Anti-IGF1R / CD221) is a humanized monoclonal antibody with high affinity that targets type-1-insulin-like growth factor receptor (IGF-1R).It shows broad-spectrum anti-tumour activity and can be used in studies of sarcomas, neuroblastoma, wilms tumor, lung cancer, malignancies, leukaemia, non-small cell lung cancer and prostate cancer. MW :150 KD.

References
[1] Houghton PJ, et al. Pediatr Blood Cancer. 2010 Jul 1;54(7):921-6.

References

[1] Houghton PJ, et al. Pediatr Blood Cancer. 2010 Jul 1;54(7):921-6.

Product Details

CAS No.	947687-12-9
Molecular Weight	150
Isotype	Human IgG1
Source	CHO
Purification	AKTA
Sterility	0.2 μM filtered
Formulation	100mMPro-Ac,20mMArg-Ac，pH5.0
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field